PDCD1 and neoplasm: Our study using a preclinical model of subcutaneous TRAMP-C2 prostate revealed that oncolytic reovirus therapy was crucial for initial priming of immune effector cells upon which the anti-PD-1 or anti-CD73 antibody therapy could then act to further improve the anti-tumor immune response.